Mark Stenhouse - May 25, 2023 Form 4 Insider Report for Phathom Pharmaceuticals, Inc. (PHAT)

Role
Director
Signature
/s/ Larry Miller, Attorney-in-Fact for Mark Stenhouse
Stock symbol
PHAT
Transactions as of
May 25, 2023
Transactions value $
$0
Form type
4
Date filed
5/30/2023, 07:01 PM
Previous filing
Dec 13, 2022
Next filing
Jun 2, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PHAT Common Stock Award $0 +9K $0.00 9K May 25, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PHAT Stock Option (Right to Buy) Award $0 +15K $0.00 15K May 25, 2023 Common Stock 15K $11.72 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Restricted Stock Units ("RSUs") were granted on May 25, 2023, pursuant to the Issuer's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing service on the Board through such vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
F2 The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuing in service on the Board through such vesting date.